Q&A with Russell Cohen: Healthcare Economics and Its Impact on IBD
DECEMBER 10, 2015
Russell Cohen, MD, director of the Inflammatory Bowel Diseases Center at The University of Chicago Medicine continued to discuss the relevance of healthcare economics specific to IBD at the 2015 Advances in Inflammatory Bowel Diseases.
"In the US the insurers don't just pay for the cost of medicine, but they pay for the overall cost of care, and some insurers are actually employers, too. If you can show that a medication per dose, but ends up decreasing hospitalizations, surgeries, ER visits, you actually may save money, or at least be cost neutral," commented Cohen.